ValuEngine lowered shares of Eagle Pharmaceuticals (NASDAQ:EGRX) from a buy rating to a hold rating in a report published on Sunday.

A number of other research firms have also recently commented on EGRX. BidaskClub raised shares of Eagle Pharmaceuticals from a hold rating to a buy rating in a research note on Saturday, December 2nd. Mizuho reaffirmed a sell rating and set a $37.00 price target on shares of Eagle Pharmaceuticals in a research note on Wednesday, November 8th. Royal Bank of Canada reaffirmed an outperform rating and set a $75.00 price target (down from $81.00) on shares of Eagle Pharmaceuticals in a research note on Thursday, November 9th. Finally, Piper Jaffray Companies reaffirmed a buy rating and set a $75.00 price target on shares of Eagle Pharmaceuticals in a research note on Friday, October 27th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The company presently has an average rating of Hold and a consensus price target of $62.33.

Eagle Pharmaceuticals (NASDAQ EGRX) traded up $0.48 during mid-day trading on Friday, hitting $58.69. 197,700 shares of the company were exchanged, compared to its average volume of 265,950. Eagle Pharmaceuticals has a 52-week low of $45.05 and a 52-week high of $97.15. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.15 and a current ratio of 5.30. The stock has a market cap of $875.75, a PE ratio of 9.45 and a beta of 1.24.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Argent Capital Management LLC bought a new stake in Eagle Pharmaceuticals during the 2nd quarter valued at about $686,000. Advisory Services Network LLC lifted its holdings in Eagle Pharmaceuticals by 52.8% during the 2nd quarter. Advisory Services Network LLC now owns 12,225 shares of the specialty pharmaceutical company’s stock valued at $964,000 after buying an additional 4,225 shares in the last quarter. U S Global Investors Inc. bought a new stake in Eagle Pharmaceuticals during the 2nd quarter valued at about $1,097,000. Vanguard Group Inc. lifted its holdings in Eagle Pharmaceuticals by 22.7% during the 2nd quarter. Vanguard Group Inc. now owns 561,820 shares of the specialty pharmaceutical company’s stock valued at $44,322,000 after buying an additional 103,760 shares in the last quarter. Finally, Capital Fund Management S.A. lifted its holdings in Eagle Pharmaceuticals by 20.1% during the 2nd quarter. Capital Fund Management S.A. now owns 59,246 shares of the specialty pharmaceutical company’s stock valued at $4,674,000 after buying an additional 9,900 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: “Eagle Pharmaceuticals (EGRX) Downgraded to Hold at ValuEngine” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/eagle-pharmaceuticals-egrx-downgraded-to-hold-at-valuengine/1794285.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.